Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 926 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: PSORIASIS Clear all

Conditions: Psoriasis
Interventions: Etanercept; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 42
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more

Conditions: Chronic Stable Plaque Psoriasis
Interventions: Placebo, 400 mg (200 mg BID), 300 mg (150 mg BID); Drug
Lead sponsor: Innovation Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 34
States / cities: Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 27 more

Conditions: Moderate to Severe Plaque Psoriasis
Interventions: 210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 67
States / cities: Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 56 more

Conditions: Psoriasis Vulgaris
Interventions: Calcipotriene plus betamethasone dipropionate ointment; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 8
States / cities: Fremont, California • San Diego, California • Maitland, Florida + 5 more

Conditions: Type 1 Diabetes Mellitus, Multiple Sclerosis, Arthritis, Rheumatoid, Crohn's Disease, Psoriasis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 60 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: New Haven, Connecticut • Atlanta, Georgia • Manhasset, New York + 3 more

Conditions: Psoriasis
Interventions: VTX958 Dose A, VTX958 Dose B, VTX958 Dose C, VTX958 Dose D, Placebo; Drug
Lead sponsor: Ventyx Biosciences, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 33 more

Conditions: Psoriasis
Interventions: PRX003, Placebo; Drug · Other
Lead sponsor: Prothena Biosciences Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 9
States / cities: San Diego, California • Coral Gables, Florida • Ocala, Florida + 6 more

Conditions: Psoriasis
Interventions: Cloderm Cream; Drug
Lead sponsor: Promius Pharma, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2012
U.S. locations: 5
States / cities: Cincinnati, Ohio • Portland, Oregon • Austin, Texas + 2 more

Conditions: Psoriasis
Interventions: CP-690,550 Ointment 1, Vehicle 1, CP-690,550 Ointment 2, Vehicle 2; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 8
States / cities: Mobile, Alabama • Los Angeles, California • Orange Park, Florida + 4 more

Conditions: Psoriasis, Psoriatic Arthritis, Psoriatic Conditions, Cardiovascular Diseases
Interventions: Care Coordinator Model; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 40 Years to 75 Years
Enrollment: 603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 20
States / cities: Scottsdale, Arizona • Fort Smith, Arkansas • Los Angeles, California + 17 more

Conditions: Plaque Psoriasis
Interventions: Not listed
Lead sponsor: Power Life Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Psoriasis
Interventions: BI 655066 (very high i.v. dose), Placebo, i.v., BI 655066 (high s.c. dose), BI 655066 (low i.v. dose), BI 655066 (high medium i.v. dose), BI 655066 (very low i.v. dose), BI 655066 (low s.c. dose), BI 655066 (high i.v. dose), Placebo, s.c., BI 655066 (low medium i.v. dose); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 7
States / cities: Burbank, California • Miami, Florida • Port Orange, Florida + 4 more

Conditions: Chronic Plaque Psoriasis
Interventions: PF-06700841, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 30
States / cities: Rogers, Arkansas • Anaheim, California • Encinitas, California + 18 more

Conditions: Psoriasis
Interventions: ARQ-151 cream 0.5%, ARQ-151 cream 0.15%, ARQ-151 vehicle cream; Drug
Lead sponsor: Arcutis Biotherapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Psoriasis Vulgaris
Interventions: 0.01% Halobetasol, 0.045% Tazarotene, 0.05% Clobetasol Propionate; Drug
Lead sponsor: Dermatology Consulting Services, PLLC; Network
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Psoriasis
Interventions: BMS-986165; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Epidermolysis Bullosa, Ichthyosis, Atopic Dermatitis, Psoriasis
Interventions: TheraClean; Device
Lead sponsor: Northwestern University; Other
Eligibility: 2 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Palmoplantar Pustulosis (PPP)
Interventions: Spesolimab, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Birmingham, Alabama • Beverly Hills, California • San Diego, California + 11 more

Conditions: Psoriatic Arthritis
Interventions: methotrexate (MTX), adalimumab (ADA); Drug · Biological
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 12
States / cities: Sun City, Arizona • Miami, Florida • Vernon Hills, Illinois + 9 more

Conditions: Psoriasis
Interventions: Med-Jet, Traditional Syringe; Device · Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Plaque Psoriasis
Interventions: clobetasol propionate spray, clobetasol propionate ointment; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 6
States / cities: Fremont, California • Vallejo, California • Detroit, Michigan + 3 more

Conditions: Psoriatic Arthritis
Interventions: Deucravacitinib, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 33
States / cities: Gilbert, Arizona • Jonesboro, Arkansas • Fontana, California + 30 more

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo, Adalimumab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Rancho Mirage, California • Duncansville, Pennsylvania

Conditions: Scalp Psoriasis
Interventions: clobetasol propionate spray 0.05%, Vehicle spray; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 4
States / cities: Los Angeles, California • Evansville, Indiana • New York, New York + 1 more

Search by objective public record fields.

Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab

Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis

Safety and Efficacy of TACLONEX Ointment in Adolescent Patients (Aged 12 to 17 Years) With Psoriasis Vulgaris

T and B Cell Responses in Autoimmune Diseases

VTX958 Versus Placebo for the Treatment of Moderate to Severe Psoriasis

Multiple Ascending Dose Study of PRX003 in Subjects With Psoriasis

Study of the Efficacy of Cloderm® Cream in the Treatment of Moderate Plaque Psoriasis

CP-690-550 Ointment For Chronic Plaque Psoriasis

Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis

Understanding Participation Habits Among Plaque Psoriasis Patients

Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis

Study To Evaluate Safety And Efficacy Of PF-06700841 In Subjects With Moderate To Severe Plaque Psoriasis

Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis

Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis

Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants

Thera-Clean® Microbubbles System in Patients With Skin Diseases

A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis

A Study of Subjects With Psoriatic Arthritis to Investigate the Effectiveness of Adalimumab Introduction Compared With Methotrexate Dose Escalation (CONTROL)

Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System

Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis

Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp